Sidaway James E, Davidson Robert G, McTaggart Fergus, Orton Terry C, Scott Robert C, Smith Graham J, Brunskill Nigel J
AstraZeneca, Safety Assessment, 23S37-69, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK.
J Am Soc Nephrol. 2004 Sep;15(9):2258-65. doi: 10.1097/01.ASN.0000138236.82706.EE.
Renal proximal tubule cells are responsible for the reabsorption of proteins that are present in the tubular lumen. This occurs by receptor-mediated endocytosis, a process that has a requirement for some GTP-binding proteins. Statins are inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase used for the therapeutic reduction of cholesterol-containing plasma lipoproteins. However, they can also reduce intracellular levels of isoprenoid pyrophosphates that are derived from the product of the enzyme, mevalonate, and are required for the prenylation and normal function of GTP-binding proteins. The hypothesis that inhibition of HMG-CoA reductase in renal proximal tubule cells could reduce receptor mediated-endocytosis was therefore tested. Five different statins inhibited the uptake of FITC-labeled albumin by the proximal tubule-derived opossum kidney cell line in a dose-dependent manner and in the absence of cytotoxicity. The reduction in albumin uptake was related to the degree of inhibition of HMG-CoA reductase. Simvastatin (e.g., statin) inhibited receptor-mediated endocytosis of both FITC-albumin and FITC-beta(2)-microglobulin to similar extents but without altering the binding of albumin to the cell surface. The effect on albumin endocytosis was prevented by mevalonate and by the isoprenoid geranylgeranyl pyrophosphate but not by cholesterol. Finally, evidence that the inhibitory effect of statins on endocytosis of proteins may be caused by reduced prenylation and thereby decreased function of one or more GTP-binding proteins is provided. These data establish the possibility in principle that inhibition of HMG-CoA reductase by statins in proximal tubule cells may reduce tubular protein reabsorption.
肾近端小管细胞负责重吸收存在于肾小管管腔中的蛋白质。这一过程通过受体介导的内吞作用来实现,该过程需要一些GTP结合蛋白。他汀类药物是3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶的抑制剂,用于治疗性降低含胆固醇的血浆脂蛋白。然而,它们也会降低细胞内类异戊二烯焦磷酸的水平,这些类异戊二烯焦磷酸来源于该酶的产物甲羟戊酸,是GTP结合蛋白的异戊二烯化和正常功能所必需的。因此,对肾近端小管细胞中HMG-CoA还原酶的抑制是否会减少受体介导的内吞作用这一假设进行了测试。五种不同的他汀类药物以剂量依赖的方式抑制了源自近端小管的负鼠肾细胞系对异硫氰酸荧光素(FITC)标记白蛋白的摄取,且无细胞毒性。白蛋白摄取的减少与HMG-CoA还原酶的抑制程度有关。辛伐他汀(如他汀类药物)对FITC-白蛋白和FITC-β2-微球蛋白的受体介导内吞作用的抑制程度相似,但不改变白蛋白与细胞表面的结合。甲羟戊酸和类异戊二烯香叶基香叶基焦磷酸可防止对白蛋白内吞作用的影响,但胆固醇则不能。最后,有证据表明他汀类药物对蛋白质内吞作用的抑制作用可能是由于异戊二烯化减少,从而导致一种或多种GTP结合蛋白的功能降低。这些数据原则上证实了近端小管细胞中他汀类药物抑制HMG-CoA还原酶可能会减少肾小管蛋白质重吸收的可能性。